Equity Overview
Price & Market Data
Price: $1.01
Daily Change: +$0.0158 / 1.56%
Range: $0.983 - $1.08
Market Cap: $17,486,248
Volume: 627,237
Performance Metrics
1 Week: 10.77%
1 Month: -9.57%
3 Months: -8.77%
6 Months: -0.95%
1 Year: 18.44%
YTD: -8.77%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.